2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Multiple Myeloma
430
Lymphoma, Large B-Cell, Diffuse
97
Leukemia, Lymphocytic, Chronic, B-Cell
88
Lymphoma, Follicular
81
Recurrence
72
Lymphoma
62
Lymphoma, Mantle-Cell
59
Neoplasms, Plasma Cell
58
Lymphoma, B-Cell, Marginal Zone
47
Lymphoma, Non-Hodgkin
46
Leukemia, Myeloid, Acute
34
Leukemia
32
Neoplasms
24
Myelodysplastic Syndromes
24
Lymphoma, B-Cell
24
Waldenstrom Macroglobulinemia
18
Hodgkin Disease
18
Smoldering Multiple Myeloma
17
Lymphoma, T-Cell, Peripheral
16
Burkitt Lymphoma
14
Hematologic Diseases
13
Lymphoma, T-Cell, Cutaneous
12
Lymphoma, T-Cell
12
Prostatic Neoplasms
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Sezary Syndrome
10
Mycosis Fungoides
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, Large-Cell, Anaplastic
9
Leukemia, Myelomonocytic, Chronic
9
Interventions
Bevacizumab
4
Temozolomide
3
Irinotecan
3
Sorafenib
2
Radiosurgery
2
pembrolizumab
1
ibrutinib
1
Vorinostat
1
Valproic Acid
1
Transcranial Magnetic Stimulation
1
Therapeutics
1
Thalidomide
1
Surveys and Questionnaires
1
Standard of Care
1
Sildenafil Citrate
1
Radiotherapy
1
Pliability
1
Plasma Exchange
1
Palliative Care
1
Nivolumab
1
Morphine
1
Methadone
1
Lenalidomide
1
Laparoscopy
1
Immunoglobulins
1
Exercise
1
Equipment and Supplies
1
Eating
1
Cytidine Triphosphate
1
Clomipramine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neurologic Manifestations
×
Lenalidomide
×
Clear all
NCT04446962
2025-09-25
LOC-R01
Institut Curie
Phase 1/2
Active not recruiting
118 enrolled